US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
biotech · Systemic Lupus Erythematosus · Primary Progressive Multiple Sclerosis (PPMS) · ZBIO
Zenas BioPharma
Zenas BioPharma drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1000 Winter St, Suite 1200, Waltham, MA 02451, US HQ
176 Employees
Public company Type
ZBIO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1000 Winter St, Suite 1200, Waltham, MA 02451, US
- Employees
- 176
- Programs
- 13
- Drugs
- 10
- Patents
- 0
Zenas BioPharma pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Zenas BioPharma drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Zenas BioPharma in public FDA and regional records.
-
Development asset linked to Zenas BioPharma in public FDA and regional records.
-
Development asset linked to Zenas BioPharma in public FDA and regional records. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
Development asset linked to Zenas BioPharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Zenas BioPharma in public FDA and regional records.
-
Development asset linked to Zenas BioPharma in public FDA and regional records.
-
Development asset linked to Zenas BioPharma in public FDA and regional records.